TriangleRuxolitinib (NCT07356245)
Ruxolitinib trial for T-cell Lymphoma (NCT07356245). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with specified T-cell lymphomas or leukemias in partial or complete remission 35–120 days after an autologous or donor stem-cell transplant. Certain low-risk ALCL cases are excluded.
The idea: take ruxolitinib twice daily by mouth through one year after transplant. It blocks JAK signals involved in cell growth and immune activity. Researchers assess relapse; donor-transplant patients are also assessed for graft-versus-host disease. Biopsies may be taken if disease progresses.
This phase 2 study plans 44 patients. Ohio State leads; two US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.